A study published in the American Journal of Cardiology determined the acute results and short- to medium-term durability of transcatheter tricuspid valve-in-valve (TVIV) implantation within surgical bioprostheses among patients with Ebstein anomaly (EA). The investigators of this study revealed that transcatheter TVIV offers a low-risk, minimally invasive alternative to surgical tricuspid valve re-replacement in patients with EA and a failing tricuspid valve bioprosthesis. It was reported that TVIV was successful in the entire study cohort and there was no procedural mortality.